Anebulo Pharmaceuticals analyst ratings
Anebulo Pharmaceuticals analyst ratings
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $2.94, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2022 | 104.08% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 410.2% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/27/2022 | 104.08% | 拉登堡·塔爾曼 | → $6 | 開始承保 | →購買 |
| 05/25/2021 | 410.2% | 基準 | → $15 | 開始承保 | →購買 |
Anebulo Pharmaceuticals Questions & Answers
AneBulo製藥公司的問題與解答
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Ladenburg Thalmann on July 27, 2022. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 104.08% upside). 1 analyst firms have reported ratings in the last year.
拉登堡·塔爾曼於2022年7月27日報道了安妮寶製藥(納斯達克：ANEB)的最新目標價。這家分析公司將目標價定為6美元，預計ANEB將在12個月內上漲至(可能上漲104.08%)。1家分析公司在過去一年公佈了評級。
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Ladenburg Thalmann, and Anebulo Pharmaceuticals initiated their buy rating.
安妮寶製藥(納斯達克代碼：ANEB)的最新分析師評級由拉登堡·塔爾曼提供，安妮寶製藥啟動了他們的買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on July 27, 2022 so you should expect the next rating to be made available sometime around July 27, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與AneBulo製藥公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AneBulo製藥的上一次評級是在2022年7月27日提交的，所以你應該預計下一次評級將在2023年7月27日左右的某個時候公佈。
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $2.94, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的AneBulo PharmPharmticals(ANEB)評級是以0.00美元至6.00美元的目標價啟動的。AneBulo PharmPharmticals(ANEB)目前的交易價格為2.94美元，在分析師的預測範圍內。
